Skip to main content

Table 1 Clinicopathological characteristics of patients

From: Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer

Variables

level

Overall

Alive

Death

P value

N

 

4522

3993

529

 

Age (mean (SD))

 

58.77 (10.65)

58.42 (10.73)

61.39 (9.70)

 < 0.001

Sex (%)

Male

2540 (56.2)

2148 (53.8)

392 (74.1)

 < 0.001

Female

1982 (43.8)

1845 (46.2)

137 (25.9)

 

Smoke (%)

No

2393 (52.9)

2205 (55.2)

188 (35.5)

 < 0.001

Yes

1401 (31.0)

1165 (29.2)

236 (44.6)

 

Unknown

728 (16.1)

623 (15.6)

105 (19.8)

 

Marital status(%)

Married (including common law)

4355 (96.3)

3843 (96.2)

512 (96.8)

0.596

Divorced

4 (0.1)

4 (0.1)

0 (0.0)

 

Single (never married)

58 (1.3)

54 (1.4)

4 (0.8)

 

Unknown

105 (2.3)

92 (2.3)

13 (2.5)

 

Histologic_Type_ICD_O_3 (%)

Adenocarcinoma

3530 (78.1)

3188 (79.8)

342 (64.7)

 < 0.001

Adenosquamous

63 (1.4)

44 (1.1)

19 (3.6)

 

Large cell carcinoma,

25 (0.6)

18 (0.5)

7 (1.3)

 

Neuroendocrine cancer

54 (1.2)

44 (1.1)

10 (1.9)

 

Non-small cell lung cancer

10 (0.2)

9 (0.2)

1 (0.2)

 

Sarcomatoid carcinoma

47 (1.0)

35 (0.9)

12 (2.3)

 

Signet ring cell carcinoma

64 (1.4)

45 (1.1)

19 (3.6)

 

Small cell carcinoma

621 (13.7)

510 (12.8)

111 (21.0)

 

Squamous cell carcinoma

1 (0.0)

1 (0.0)

0 (0.0)

 

Undifferentiated carcinoma

107 (2.4)

99 (2.5)

8 (1.5)

 

Grade (%)

other

503 (11.1)

496 (12.4)

7 (1.3)

 < 0.001

Grade IModerately differentiated; Grade II

1538 (34.0)

1362 (34.1)

176 (33.3)

 

Poorly differentiated; Grade III

1103 (24.4)

906 (22.7)

197 (37.2)

 

Undifferentiated; anaplastic; Grade IV,

7 (0.2)

5 (0.1)

2 (0.4)

 

Unknown

1371 (30.3)

1224 (30.7)

147 (27.8)

 

Loratadine use

No

3223 (71.3)

2812 (70.4)

411 (77.7)

 

Use

1299 (28.7)

1181 (29.6)

118 (22.3)

0.001